BeyondSpring EBITDA 2015-2025 | BYSI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

BeyondSpring ebitda from 2015 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

BeyondSpring ebitda from 2015 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$245.5B
Amgen (AMGN)	$159.6B
Gilead Sciences (GILD)	$146.9B
Vertex Pharmaceuticals (VRTX)	$100.7B
Bristol Myers Squibb (BMY)	$98.6B
CSL (CSLLY)	$85.1B
GSK (GSK)	$80.2B
Regeneron Pharmaceuticals (REGN)	$61.5B
Alnylam Pharmaceuticals (ALNY)	$58.8B
Argenex SE (ARGX)	$40B
BioNTech SE (BNTX)	$27.3B
Insmed (INSM)	$27B
Royalty Pharma (RPRX)	$21.2B
Biogen (BIIB)	$20.3B
Incyte (INCY)	$17B
Illumina (ILMN)	$15.4B
Genmab (GNMSF)	$15.3B
Genmab (GMAB)	$15B
Ascendis Pharma (ASND)	$12.1B
BioMarin Pharmaceutical (BMRN)	$11B
QIAGEN (QGEN)	$11B
Moderna (MRNA)	$10.9B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.3B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.6B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.1B
Halozyme Therapeutics (HALO)	$7.9B